![]() |
Trials |
A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years.Cancer type: Leukemia Phase: II Principal Investigator: Gjertsen Bjørn Tore Country: NO Keywords: Norway, Bergen Status: Inclusion completed |